Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Neurobiol Dis. 2019 Jan 30;125:123–134. doi: 10.1016/j.nbd.2019.01.020

Figure 4.

Figure 4.

Combination (COMB) treatment significantly reduced brain Aβ levels.

(a) Quantitative analysis of Aβ40 and Aβ42 levels in mice brains homogenate as measured by ELISA (n=5–6 mice per group). (b) Representative brain sections of 5XFAD mice treated with etodolac (ETO), α-tocopherol (Tph), and COMB stained with 6E10 antibody to quantify total Aβ load (green) and anti-collagen antibody to detect microvessels (red), and their optical density quantitation in both brain regions, cortex and hippocampus (n=9 mice for control group and n=5 mice for treatment groups). Scale bar, 50 μm. Mice were treated with ETO, Tph or COMB at 10 mg/kg/day each for 30 days. Data are presented as mean ± SEM. ns = not significant; ** p < 0.01, *** p < 0.001 compared to CTRL; # p < 0.05, ## p < 0.01, ### p < 0.001represent COMB compared to ETO alone; @@@ p < 0.001represent COMB compared to Tph alone.